Show simple item record

dc.contributor.authorBauch, Chris T.
dc.contributor.authorLi, Meng
dc.contributor.authorChapman, Gretchen
dc.contributor.authorGalvani, Alison P.
dc.date.accessioned2023-05-01 18:32:54 (GMT)
dc.date.available2023-05-01 18:32:54 (GMT)
dc.date.issued2010-02-10
dc.identifier.urihttps://doi.org/10.1016/s1473-3099(10)70004-9
dc.identifier.urihttp://hdl.handle.net/10012/19379
dc.descriptionThe final publication is available at Elsevier via https://doi.org/10.1016/s1473-3099(10)70004-9. © 2010. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.description.abstractThe recently licensed human papillomavirus (HPV) vaccine can prevent most cervical cancers. However, continued screening is necessary in vaccinated women to prevent cancers caused by high-risk HPV types not included in the vaccine. In the HPV vaccine era, there is new concern that vaccinated women will reduce their rate of screening due to an exaggerated sense of protection from the vaccine. Some have suggested this could paradoxically lead to an increase in the incidence of cervical cancer cases. Here, we present a simple mathematical model suggesting that it would be difficult for such a perverse outcome to occur. We make a conservative estimate that screening rates in vaccinated women would have to decline by at least 39% for the incidence of cervical cancer in a population to increase relative to pre- vaccine levels. We also present results from a new nationwide survey of attitudes in the United States that are consistent with a decline of less than 39%. Finally, the model uncovers a surprising observation that in populations where screening rates are high in the pre-vaccine era, screening rates in vaccinated women can fall less before perverse outcomes start to occur.en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.ispartofseriesThe Lancet Infectious Diseases;
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectcervical screeningen
dc.subjectmathematical modelen
dc.subjectcervical canceren
dc.subjecthuman papillomavirus vaccineen
dc.titleCervical screening adherence in era of HPV vaccination: how low is too low?en
dc.title.alternativeAdherence to cervical screening in the era of human papillomavirus vaccination: how low is too low?en
dc.typeArticleen
dcterms.bibliographicCitationBauch, C. T., Li, M., Chapman, G., & Galvani, A. P. (2010). Adherence to cervical screening in the era of human papillomavirus vaccination: How low is too low? The Lancet Infectious Diseases, 10(2), 133–137. https://doi.org/10.1016/s1473-3099(10)70004-9en
uws.contributor.affiliation1Faculty of Mathematicsen
uws.contributor.affiliation2Applied Mathematicsen
uws.typeOfResourceTexten
uws.peerReviewStatusRevieweden
uws.scholarLevelFacultyen


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial 4.0 International

UWSpace

University of Waterloo Library
200 University Avenue West
Waterloo, Ontario, Canada N2L 3G1
519 888 4883

All items in UWSpace are protected by copyright, with all rights reserved.

DSpace software

Service outages